Quest Diagnostics Inc

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics Expected to Report Flat Revenue Growth in Fiscal 2018

    Myriad Genetics (MYGN) expects to report revenues in the range of $750 million–$770 million in fiscal 2018 (ended June 30, 2018).

    By Margaret Patrick
  • uploads///laboratory _
    Company & Industry Overviews

    How Quest Diagnostics Is Positioned in 2018

    Quest Diagnostics generated revenues of $1.92 billion in the second quarter of 2018 as compared with $1.86 billion in the second quarter of 2017.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Fresenius Medical Care Is a Global Leader in the Dialysis Segment

    In addition to selling dialysis products, Fresenius Medical Care also offers dialysis treatment and associated laboratory services to patients through its network of 3,690 clinics.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    North America: Fresenius Medical Care’s Major Target Market in 2017

    In 2Q17, Fresenius Medical Care (FMS) reported revenues close to 3.3 billion euros, which represents year-over-year growth of ~11%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Fresenius Medical Care’s Net Profit Margins Could Fall Slightly

    For fiscal 2017, Wall Street analysts have projected Fresenius Medical Care’s net profit margins to be close to 6.2%, which is a YoY decline of ~70 basis points.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Analysts View Fresenius Medical Care and Its Peers in August 2017

    In 1H17, Fresenius Medical Care (FMS) reported revenues close to 9.0 billion euros, which represents 14% YoY growth. At the end of 2Q17, the company operated 3,690 dialysis clinics around the world.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics’ Multi-Pronged Strategy to Accelerate Growth

    Quest Diagnostics (DGX) expects to witness a 3.0%–5.0% long-term revenue growth rate in the future with earnings growth of 5.0%–9.0%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics Is Targeting 3 Focus Areas to Accelerate Growth

    Since 2012, Quest Diagnostics (DGX) has spent about $1.0 billion on capital investments and $1.0 billion on ten acquisitions to support inorganic growth.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics Is Making Steady Progress in 5-Point Strategy

    Since 2012, Quest Diagnostics (DGX) has been working on a five-point strategy to boost revenue growth and improve quality, service, and efficiency.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics Projects Run Rate Savings by End of 2017

    Quest Diagnostics (DGX) has projected a run rate savings worth $1.3 billion by the end of 2017. In 2016, it managed to save up to $1.1 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics’ Reference Testing, Hospital Outreach Segment

    With services offered to about half of the total hospitals, Quest Diagnostics (DGX) has become a leading provider of reference testing services in the United States.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics Could Get Greater Share of Laboratory Segment

    With around 50.0% of hospitals being served by Quest Diagnostics (DGX), the company has become a leading player in the fragmented US laboratory market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Quest Diagnostics’ Five Point Business Strategy Matters in 2016

    If Quest Diagnostics succeeds in implementing its five-point business strategy going forward, it should boost the company’s share price and USMV.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    LabCorp Trades at Discounted PE Multiples Compared with Peers in 1Q16

    In a survey of 22 brokerage companies on April 26, 2016, about 71.4% of the brokers rated LabCorp (LH) a “buy,” while 28.6% rated it a “hold.” None of the brokers rated it a “sell.”

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    LabCorp’s Growth Drivers in 1Q16: Organic Growth, Acquisitions

    In 1Q16, LabCorp’s (LH) national clinical laboratory business, LabCorp Diagnostics, accounted for 69.3% of the company’s total revenues.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Quest Diagnostics’ Growth Restoration Strategy

    Quest Diagnostics has been focusing on developing sales and marketing expertise, increasing esoteric testing, and building relationships with hospitals.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Understanding Quest Diagnostics’ Valuation Multiple Compared to Those of Peers

    Quest Diagnostics trades at a premium multiple compared to Lab Corp of America and at a big discount compared to peers Davita Healthcare and IDEXX Labs.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Revenue Growth Initiatives Drove LabCorp’s Performance in 1Q16

    In 1Q16, LabCorp (LH) reported strong revenue and earnings growth due to the effective implementation of multiple strategic initiatives. LabCorp is the world’s leading healthcare diagnostics company.

    By Margaret Patrick
  • uploads///segmentation
    Company & Industry Overviews

    An Overview of Thermo Fisher Scientific’s Business Model

    Thermo Fisher Scientific (TMO) has made a number of acquisitions over the years, resulting in the expansion of the company’s product portfolio with the inclusion of a number of premium brands.

    By Sarah Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.